EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dissecting Immune Determinants in Lesional Skin of Cutaneous T-Cell Lymphoma During Mogamulizumab Therapy

Xiao Ni iD, Wei Han, Niharika Kunta, Meghali Goswami, Jared K Burks iD, Ye Zheng, Youn H Kim, Madeleine Duvic

Cancers · 21.07.2026 · 18 (14) · 2348

DOI: 10.3390/cancers18142348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 21.07.2026. Verfasst von Xiao Ni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, The University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mycosis fungoides (MF) and Sézary syndrome (SS) are the predominant cutaneous T-cell lymphomas. Although malignant T cells in MF/SS overexpress CCR4 and respond to the anti-CCR4 antibody mogamulizumab, skin response rates vary. We hypothesized that immune components within the tumor microenvironment contribute to differential outcomes.

Methods

Imaging mass cytometry with a 37-antibody panel was used to characterize immune and structural elements in FFPE tissues from sixteen MF/SS patients (6 MF, 10 SS) treated with Mogamulizumab, including seven skin responders and nine non-responders. Single-cell phenotyping and spatial analyses were performed using the Visiopharm® Phenoplex™ platform, with supervision.

Results

We identified 68,974 cells pre-treatment and 58,852 cells post-treatment. Malignant CD4+ T cells showed reduced baseline CD27, CD103, CD25, and ICOS expression compared with non-malignant CD4+ cells. Baseline MF lesions were enriched for IL-13+ and CD103+ malignant T cells, whereas SS lesions contained higher proportions of CD27+ and LAG3+ cells. IL 13+ malignant cells decreased after treatment, most prominently in MF. Myeloid profiles differed by disease and response: MF lesions exhibited baseline enrichment of M1-like macrophages (CD86+, HLA-DR+), while SS lesions were predominantly M2-polarized macrophages (CD163+, CD206+). Responders showed increased M1-like macrophages, whereas non-responders displayed reduced M1-features. An increase in DC3-like cells was observed in non-responders following treatment.

Conclusions

This single-cell spatial atlas reveals shared and subtype-specific immune features in MF/SS. Th2-skewed malignant T-cell status and myeloid polarization correlate with clinical response, supporting their potential as spatial biomarkers for patient stratification in mogamulizumab therapy.

Schlagwörter

Stichwörter der Autor:innen

CCR4Sézary syndromecutaneous T-cell lymphoma (CTCL)imaging mass cytometrymogamulizumabmycosis fungoidestumor microenvironment

Autor:innen und Institutionen

  • Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA.

ORCID-Profile: Xiao Ni, Jared K Burks

Förderung

  • NCI NIH HHS
  • The University of Texas MD Anderson Cancer Center
  • MD Anderson Cancer Center
  • Fred Pearce Fund

Zitieren

APA

Ni, X., Han, W., Kunta, N., Goswami, M., Burks, J. K., Zheng, Y., Kim, Y. H., & Duvic, M. (2026). Dissecting Immune Determinants in Lesional Skin of Cutaneous T-Cell Lymphoma During Mogamulizumab Therapy. Cancers, 18(14), 2348. https://doi.org/10.3390/cancers18142348

Vancouver

Ni X, Han W, Kunta N, Goswami M, Burks JK, Zheng Y, et al. Dissecting Immune Determinants in Lesional Skin of Cutaneous T-Cell Lymphoma During Mogamulizumab Therapy. Cancers. 2026;18(14):2348. doi:10.3390/cancers18142348

BibTeX
@article{Ni2026,
  author = {Ni, Xiao and Han, Wei and Kunta, Niharika and Goswami, Meghali and Burks, Jared K and Zheng, Ye and Kim, Youn H and Duvic, Madeleine},
  title = {Dissecting Immune Determinants in Lesional Skin of Cutaneous T-Cell Lymphoma During Mogamulizumab Therapy},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {14},
  pages = {2348},
  doi = {10.3390/cancers18142348}
}
Kostenlos starten →